into CEA itself as a biomarker and trying to see if it can be targeted and basically in a different way of using a more novel ADC type of component and trying also looking if there could be a better designed ADC. to hopefully target CEA itself. This is an exciting first in human phase one trial that’s targeting CEA as an ADC in a novel design in the sense of both its linker, its payload and its abilities to internalize in a more efficient way. I think one of the major aspects of this ADC is that it’s able to show high response rates, which were previously not seen in other prior CEA ADCs and really showing a broad aspects of actually targeting lung cancer. patients in a way that we can now potentially even use this as a biomarker, potentially in the future, but also as a way to expand the portfolios of potentially using an ADC in lung cancer itself. So this is a early first in human preliminary toxicity profiling that we are seeing right now in this ADC. Major toxicities were mainly cytopenias, anemia, thrombocytopenias and neutropenias. Other adverse events were also GI side effects, nausea, vomiting, and those were also noted in the trial. In the aspects of also toxicities is the low discontinuation rates that we have also seen with this ADC, really prompting a, you know, exciting aspect of this ADC in the sense of showing that it can be tolerable, but also showing responses in the same way. since this is a first in human type of trial, these patients were heavily pretreated with more than two to three lines of treatment as the majority of the patients in this trial. So the response rates were very robust and actually very, able to be seen as very efficient compared to other ADCs in this heavily pretreated population. The preliminary or R rates that we are seeing is around 60 % in the CEA high group. And those are some of the more encouraging type of top line results that we’re seeing and further expanding into other type of trial designs in this aspect. CEA or also known as CEA CKAM5 is one of these biomarker that we have seen in the past, especially in GI cancers as a way to target potentially these type of tumors. But now that we’re expanding into lung cancer, that’s one of the major ones that we are trying to see with this first in human ADC. And I think this is promising in the sense that this is a potential highly expressed biomarker in lung cancer that can actually broadly treat and target patients at this point.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
